|
|
Volumn 517, Issue 7534, 2015, Pages 253-254
|
|
First biosimilar drug set to enter US market
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
BIOSIMILAR AGENT;
FILGRASTIM;
GENERIC DRUG;
GRANULOCYTE COLONY STIMULATING FACTOR;
MONOCLONAL ANTIBODY;
RECOMBINANT PROTEIN;
CHEMICAL STRUCTURE;
CHEMISTRY;
DRUG INDUSTRY;
ECONOMICS;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LEGISLATION AND JURISPRUDENCE;
NEOPLASMS;
PATENT;
SUPPLY AND DISTRIBUTION;
UNCERTAINTY;
UNITED STATES;
ANTIBODIES, MONOCLONAL, HUMANIZED;
BIOSIMILAR PHARMACEUTICALS;
DRUG INDUSTRY;
DRUGS, GENERIC;
GRANULOCYTE COLONY-STIMULATING FACTOR;
HUMANS;
MODELS, MOLECULAR;
NEOPLASMS;
PATENTS AS TOPIC;
RECOMBINANT PROTEINS;
UNCERTAINTY;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 84922657866
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/517253A Document Type: Note |
|
Times cited : (13)
|
|
References (0)
|